677P - Consecutive complete radical surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in patients with peritoneal carcinomat...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Gastrointestinal Cancers
Surgical Oncology
Biological Therapy
Radiation Oncology
Presenter Isabel Ramos
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors I. Ramos1, O. Crusellas Maña2, J. Castellvi3, G. Galofre4, G. Soler5, F. Losa6, M. Martin7, P. Barrios4
  • 1Surgery, CSI, 08970 - Sant Joan Despí/ES
  • 2General Surgery, Hospital Sant Joan Despí Moises Broggi, 08970 - Barcelona/ES
  • 3Surgery, CSI, Sant Joan Despí/ES
  • 4Surgery, CSI, 08970 - Sant Joan Despi/ES
  • 5Medical Oncology, ICO, Hospitalet/ES
  • 6Medical Oncology, Hospital General de L´Hospitalet, 08906 - Barcelona/ES
  • 7Epidemiology, CSI, 08970 - Sant Joan Despi/ES



CRS + HIPEC offers clinical benefits 0ver conventional treatment in certain types of Peritoneal Surface Malignancies (PSM). This type of treatment is performed with curative intent, and considered standard therapy in pseudomyxoma peritonei, peritoneal mesothelioma and PC from colorectal and appendiceal tumors. It is recommended in primary as well as recurrent ovarian tumors. There is consensus in PC of gastric origin and other infrequent PSM. International Health Agencies recommend using this treatment modality at highly specialized centers, by an experience team able to ensure efficacy and safety results, under carefully controlled research programs, regularly evaluated.


From September06 to April14, 466 pt swith PC from different PSM types have been treated with 513 CRS + HIPEC procedures. 200 pts had PC from colon tumors, 99 pseudomyxoma peritonei, 78 recurrent ovarian cancer, 26 gastric PC, 21 appendiceal tumors, 16 malignant peritoneal mesothelioma, 11 no-GIST peritoneal sarcomatosis, 8 rectum tumors, 5 urachus origin and 4 from small bowel tumors. 79.9% had chemotherapy prior to CRS + HIPEC, and 91.2% prior surgery. Mean PCI 13/39. CRS achieved in 95.4%. HIPEC adjusted the type of chemotherapy agent and exposure time to the PSM. Mean HIPEC temp: 42.5°C. Mean op time was 368 min. Mean ICU and hospital stays, 2d and 13.1 d, respectively.


A third party is currently auditing these preliminary results. Morbidity: 25.5%. Reoperations: 3.4%. Anastomotic dehiscence's: 0%. Hospital readmissions: 4.6%. 30-day mortality: 1 pt Mean follow up: 24.7m. 1y predicted survival: 90.3%. Mean sv: 46.2m. Colon PC: sv probability at 12m: 91.5%, 3y sv 48.3%, 5y sv: 32%. Mean sv 41.3m. Pseudomyxoma peritonei: 1y sv: 96.9%, 3y sv: 87.4%. Mean sv 67m. Recurrent ovarian cancer: 1y sv: 93.1%. Mean sv 41.6m and median sv 45.4m. Appendiceal PC: 1y sv: 84%. Mean sv 36.8 and median sv 35.2m. Gastric PC: 1y sv: 66.3%. Median sv 27.2m Malignant peritoneal mesothelioma: sv probability at 12m: 79.3%. Mean sv 35.4m and 5y predicted sv 41%.


Our experience confirmed that CRS + HIPEC offers clinical benefits over conventional treatment in certain types of Peritoneal Surface Malignancies (PSM), as described in other series.


All authors have declared no conflicts of interest.